Topic: nanobody

Depression is a neuropsychiatric condition affecting 5% of the population and involving loss of interest, low mood, and anhedonia. Depression has been ranked as the third cause of the burden of disease worldwide in 2008 by the World Health Organization WHO. Depression molecular etiology is complex and still not fully understood. Common limitations of gold standard small molecule drugs include poor efficacy, off target side effects and difficult druggability of many targets. In this study we report a radically different approach deploying small engineered single domain antibodies (nanobody) tar